A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

Promrat, Kittichai, Lutchman, Glen, Uwaifo, Gabriel I., Freedman, Renee J., Soza, Alejandro, Heller, Theo, Doo, Edward, Ghany, Marc +6 more·2004·Hepatology
DOI 10.1002/hep.20012

Cited by (722)

Items 101–200 of 722

  1. Role of Radiologic Modalities in the Management of Non-alcoholic Steatohepatitis
    Phunchai Charatcharoenwitthaya, Keith D. Lindor · 2007 · Clinics in Liver Disease
  2. Pathophysiology of nonalcoholic steatohepatitis.
    Arthur J. McCullough · 2006 · PubMed
  3. Comparative MR study of hepatic fat quantification using single‐voxel proton spectroscopy, two‐point dixon and three‐point IDEAL
    Hyeonjin Kim, Sara E. Taksali, Sylvie Dufour, Douglas E. Befroy, T. Robin Goodman, Kitt Falk Petersen, Gerald I. Shulman, Sonia Caprio, Robert Todd Constable · 2008 · Magnetic Resonance in Medicine
  4. Beyond insulin resistance
    Jacquelyn J. Maher, Pablo León, James C. Ryan · 2008 · Hepatology
  5. Non‐alcoholic fatty liver disease from pathogenesis to management: an update
    Giovanni Musso, Roberto Gambino, Maurizio Cassader · 2009 · Obesity Reviews
  6. Liver Disease in Patients With Diabetes Mellitus
    Stephen A. Harrison · 2005 · Journal of Clinical Gastroenterology
  7. Nonalcoholic Steatohepatitis and the Metabolic Syndrome
    Brent A. Neuschwander‐Tetri · 2005 · The American Journal of the Medical Sciences
  8. Nonalcoholic fatty liver disease
    Erickson, Sandra K. · 2009 · Journal of Lipid Research
  9. Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients
    Mazen Noureddin, Katherine P. Yates, Ivana A. Vaughn, Brent A. Neuschwander‐Tetri, Arun Jayant Sanyal, Arthur J. McCullough, Raphael B. Merriman, Bilal Hameed, Edward C. Doo, David Erwin Kleiner et al. · 2013 · Hepatology
  10. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease
    Hyohun Park, Toshihide Shima, Kanji Yamaguchi, Hironori Mitsuyoshi, Masahito Minami, Kohichiroh Yasui, Yoshito Itoh, Toshikazu Yoshikawa, Michiaki Fukui, Goji Hasegawa et al. · 2010 · Journal of Gastroenterology
  11. Non-alcoholic steatohepatitis: From cell biology to clinical practice
    Helena Cortez‐Pinto, Miguel Carneiro de Moura, Christopher Paul Day · 2005 · Journal of Hepatology
  12. Pathogenesis of Non-alcoholic Steatohepatitis: Human Data
    John M. Edmison, Arthur J. McCullough · 2007 · Clinics in Liver Disease
  13. The peroxisome: still a mysterious organelle
    Michael Schrader, H. Dariush Fahimi · 2008 · Histochemistry and Cell Biology
  14. A pilot study of orlistat treatment in obese, non‐alcoholic steatohepatitis patients
    Stephen A. Harrison, Chris Fincke, D. Helinski, Sigurd Torgerson, Paul Hideyo Hayashi · 2004 · Alimentary Pharmacology & Therapeutics
  15. Nonalcoholic fatty liver disease: An overview of current insights in pathogenesis, diagnosis and treatment
    Tim C. M. A. Schreuder, Bart J. Verwer, Carin MJ van Nieuwkerk, Chris Jacob Johan Mulder · 2008 · World Journal of Gastroenterology
  16. Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD)
    Mohamed H. Ahmed, Christopher D. Byrne · 2007 · Drug Discovery Today
  17. Non-alcoholic Fatty Liver Disease and Metabolic Syndrome—Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology
    Ajay Kumar. Duseja, Shivaram Prasad Singh, Vivek A. Saraswat, Subrat Kumar Acharya, Yogesh Kumar Chawla, Subhankar Chowdhury, Radha Krishan Dhiman, Rohinivilasam Vasukutty Jayakumar, Kaushal Madan, Sri P. Misra et al. · 2015 · Journal of Clinical and Experimental Hepatology
  18. The Evolving Role of Leptin and Adiponectin in Chronic Liver Diseases
    Emmanuel A. Tsochatzis, George Papatheodoridis, Athanasios J. Archimandritis · 2006 · The American Journal of Gastroenterology
  19. Effect of vitamin E on aminotransferase levels and insulin resistance in children with non‐alcoholic fatty liver disease
    Valério Nobili, Melania Manco, Rita De Vito, Paolo Ciampalini, Fiorella Piemonte, Matilde Marcellini · 2006 · Alimentary Pharmacology & Therapeutics
  20. Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease
    G. Masterton, John N. Plevris, Peter Clive Hayes · 2009 · Alimentary Pharmacology & Therapeutics
  21. Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH
    Kumiko Shiba, Kyoichiro Tsuchiya, Chikara Komiya, Yasutaka Miyachi, Kentaro Mori, Noriko Shimazu, Shinobu Yamaguchi, Naomi Ogasawara, Makoto Katoh, Michiko Itoh et al. · 2018 · Scientific Reports
  22. Non‐alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non‐diabetic men. Role of visceral adipose tissue
    Giovanni Targher, L. Bertolini, Luca Scala, Giacomo Zoppini, Luciano Zenari, Giancarlo Falezza · 2005 · Diabetic Medicine
  23. Mitochondrial metabolic dysfunction and non-alcoholic fatty liver disease: new insights from pathogenic mechanisms to clinically targeted therapy
    Youwei Zheng, Shiting Wang, Jialiang Wu, Yong Wang · 2023 · Journal of Translational Medicine
  24. PEDIATRIC OBESITY AND INSULIN RESISTANCE: Chronic Disease Risk and Implications for Treatment and Prevention Beyond Body Weight Modification
    Martha Liliana Cruz, Gabriel Q. Shaibi, Marc J. Weigensberg, Donna Spruijt‐Metz, Geoff D.C. Ball, Michael I. Goran · 2005 · Annual Review of Nutrition
  25. Impact of Diabetes on the Severity of Liver Disease
    Ingrid J. Hickman, Graeme A. Macdonald · 2007 · The American Journal of Medicine
  26. Predictors of Acquired Lipodystrophy in Juvenile-Onset Dermatomyositis and a Gradient of Severity
    April Bingham, Gulnara Mamyrova, Kristina I. Rother, Elif A Oral, Elaine K. Cochran, Ahalya Premkumar, David Erwin Kleiner, Laura James‐Newton, Ira N. Targoff, Janardan P. Pandey et al. · 2008 · Medicine
  27. Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
    Chehrehgosha, Haleh, Sohrabi, Masoud Reza, Ismail-Beigi, Faramarz, Malek, Mojtaba, Reza Babaei, Mohammad, Zamani, Farhad, Ajdarkosh, Hossein, Khoonsari, Mahmood, Fallah, Afshin Eshghi, Khamseh, Mohammad E. · 2021 · Diabetes Therapy
  28. Nonalcoholic Fatty Liver Disease as a Complication of Insulin Resistance
    Manal F. Abdelmalek, Anna Mae Diehl · 2007 · Medical Clinics of North America
  29. IL-1 Signaling in Obesity-Induced Hepatic Lipogenesis and Steatosis
    Kimberly A. Negrin, Rachel J. Roth Flach, Marina T. DiStefano, Anouch Matevossian, Randall H. Friedline, DaeYoung Jung, Jason K. Kim, Michael Czech · 2014 · PLoS ONE
  30. Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis.
    Suzanne M. de la Monte, Lisa Longato, Ming Tong, Jack R. Wands · 2009 · PubMed
  31. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design
    Naga Chalasani, Arun Jayant Sanyal, Kris V. Kowdley, Patricia R. Robuck, Jay H. Hoofnagle, David Erwin Kleiner, Aynur Ünalp, James A. Tonascia · 2008 · Contemporary Clinical Trials
  32. Review article: current management of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis
    Zobair M. Younossi · 2008 · Alimentary Pharmacology & Therapeutics
  33. Thiazolidinediones: effects on insulin resistance and the cardiovascular system
    CATHERINE E. QUINN, Paul Hamilton, Christopher Lockhart, Gary Eugene McVeigh · 2007 · British Journal of Pharmacology
  34. Glucose dysregulation and hepatic steatosis in obese adolescents
    Anna M. G. Cali, Ana Mayra de Oliveira, Hyeon-Jin Kim, Shu Chen, Miguel Reyes‐Múgica, Sandra Escalera, James Dziura, Sara E. Taksali, Romy Kursawe, Melissa M. Shaw et al. · 2009 · Hepatology
  35. How safe is the use of thiazolidinediones in clinical practice?
    Rizos, CV, Elisaf, Moses, Mikhailidis, DP, Liberopoulos, EN · 2009 · Expert Opinion on Drug Safety
  36. Non-alcoholic fatty liver disease: current concepts and management strategies
    David Adams, Geoffrey H. Haydon, Chris Day · 2006 · Clinical Medicine
  37. Nonalcoholic Fatty Liver Disease in Women
    Ayako Suzuki, Manal F. Abdelmalek · 2009 · Women s Health
  38. PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty‐acid metabolic enzymes
    Yeon Seok Seo, Ji Hoon Kim, Nam Young Jo, Kyung Mook Choi, Sei Hyun Baik, Jong‐Jae Park, Jae J. Kim, Kwan Soo Byun, Young‐Tae Bak, Chang Hong Lee et al. · 2006 · Journal of Gastroenterology and Hepatology
  39. Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat?
    Claire Z. Larter, Geoffrey C. Farrell · 2005 · Journal of Hepatology
  40. Betaine improved adipose tissue function in mice fed a high-fat diet: a mechanism for hepatoprotective effect of betaine in nonalcoholic fatty liver disease
    Zhigang Wang, Tong Yao, Maria Pini, Zhanxiang Zhou, Giamila Fantuzzi, Zhenyuan Song · 2010 · American Journal of Physiology-Gastrointestinal and Liver Physiology
  41. A Randomized, Double Blind, Placebo-Controlled Trial of Pioglitazone in Combination with Riluzole in Amyotrophic Lateral Sclerosis
    Luc Dupuis, Reinhard Dengler, Michael Thomas Heneka, Thomas Meyer, Stephan Zierz, Jan Kassubek, Wilhelm Fischer, Franziska Steiner, Eva Lindauer, Markus Otto et al. · 2012 · PLoS ONE
  42. Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease
    Eric R. Kallwitz, Alan McLachlan, Scott J. Cotler · 2008 · World Journal of Gastroenterology
  43. Pharmacotherapy of type 2 diabetes: An update and future directions
    Antea J. DeMarsilis, Niyoti Reddy, Chrysoula Boutari, Andreas Filippaios, Elliot Sternthal, Niki Katsiki, Christos Socrates Mantzoros · 2022 · Metabolism
  44. Resolution of nonalcoholic steatohepatits after gastric bypass surgery
    Liu, Xiuli, Lazenby, Audrey J., Clements, Ronald H., Jhala, Nirag, Abrams, Gary A. · 2007 · Obesity Surgery
  45. Prevention and Treatment of the Metabolic Syndrome
    Stella Styliani Daskalopoulou, Dimitri P. Mikhailidis, Moses Elisaf · 2004 · Angiology
  46. Noninvasive Assessment of Hepatic Steatosis
    Sameer M. Mazhar, Masoud Shiehmorteza, Claude B. Sirlin · 2008 · Clinical Gastroenterology and Hepatology
  47. Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese children
    Chunlin Wang, Li Liang, Junfen Fu, Chaochun Zou, Fang Hong, Jin-Zheng Xue, Jin-Rui Lu, Xiang-Min Wu · 2008 · World Journal of Gastroenterology
  48. Non‐alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C‐reactive protein in Hispanics
    Arnoldo J. Riquelme, Marco A. Arrese, Alejandro Soza, Arturo Morales, Rene F. Baudrand, Rosa María Pérez‐Ayuso, Robinson G. Gonzalez, Manuel G. Alvarez, Verónica Hernández, María José García‐Zattera et al. · 2008 · Liver International
  49. Mechanisms and implications of age-related changes in the liver: nonalcoholic Fatty liver disease in the elderly
    Gan, Lay, Chitturi, Shivakumar, Farrell, Geoffrey C. · 2011 · Current Gerontology and Geriatrics Research
  50. Impact of obesity on treatment of chronic hepatitis C†
    Michael Charlton, Paul J. Pockros, Stephen A. Harrison · 2006 · Hepatology
  51. The Liver-Brain Axis of Alcohol-Mediated Neurodegeneration: Role of Toxic Lipids
    Suzanne M. de la Monte, Lisa Longato, Ming Tong, Sarah M. DeNucci, Jack R. Wands · 2009 · International Journal of Environmental Research and Public Health
  52. Non-alcoholic steatohepatitis and metabolic syndrome
    Mariana Verdelho Machado, Helena Cortez‐Pinto · 2006 · Current Opinion in Clinical Nutrition & Metabolic Care
  53. The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial
    Yumie Takeshita, Toshinari Takamura, Masao Honda, Yuki Kita, Yoh Zen, Kenichiro Kato, Hirofumi Misu, Tsuguhito Ota, Mikiko Nakamura, Kazutoshi Yamada et al. · 2014 · Diabetologia
  54. Narrative Review: Hepatobiliary Disease in Type 2 Diabetes Mellitus
    Keith G. Tolman, Vivian Andrew Fonseca, Meng Hee Tan, Anthony S. Dalpiaz · 2004 · Annals of Internal Medicine
  55. Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?
    Agostino Di Ciaula, Salvatore Passarella, Harshitha Shanmugam, Marica Noviello, Leonilde Bonfrate, David Q.‐H. Wang, Piero Portincasa · 2021 · International Journal of Molecular Sciences
  56. Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study
    Giorgia Anna Garinis, Barbara Fruci, A Mazza, Martina De Siena, S. Abenavoli, Elio Gulletta, Valeria Ventura, Marta Greco, Ludovico Abenavoli, Antonino Belfiore · 2010 · International Journal of Obesity
  57. Diabetes and liver disease: An ominous association
    Simona Moscatiello, Rita Manini, Giulio Marchesini · 2006 · Nutrition Metabolism and Cardiovascular Diseases
  58. Effect of canagliflozin on liver function tests in patients with type 2 diabetes
    Lawrence A. Leiter, Thomas M. Forst, David Polidori, Dainius A. Balis, John Xie, Sue Sha · 2015 · Diabetes & Metabolism
  59. Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease
    Michael Charlton, Paul Angulo, Naga Chalasani, Ralph Merriman, Kimberly Viker, Phunchai Charatcharoenwitthaya, Schuyler O. Sanderson, Samer Gawrieh, Anuradha Krishnan, Keith D. Lindor · 2008 · Hepatology
  60. Signalling mechanisms linking hepatic glucose and lipid metabolism
    Weickert, M. O., Pfeiffer, A. F. H. · 2006 · Diabetologia
  61. Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes
    Sathyanarayana, Padma, Jogi, Medhavi, Muthupillai, Raja, Krishnamurthy, Ramkumar, Samson, Susan L., Bajaj, Mandeep · 2011 · Obesity
  62. Pathology of nonalcoholic steatohepatitis
    E.M. Brunt · 2005 · Hepatology Research
  63. Troglitazone and liver injury
    Mario Chojkier · 2005 · Hepatology
  64. Effects of pentoxifylline on nonalcoholic fatty liver disease: A meta-analysis
    Juan Du · 2014 · World Journal of Gastroenterology
  65. Diabetes in chronic liver disease: from old concepts to new evidence
    Antonio Picardi, Delia D’Avola, Umberto Vespasiani Gentilucci, Giovanni Galati, Enrica Fiori, Sandro Spataro, Antonella Afeltra · 2006 · Diabetes/Metabolism Research and Reviews
  66. Pharmacological advances in mitochondrial therapy
    Aarti Singh, Danilo Faccenda, Michelangelo Campanella · 2021 · EBioMedicine
  67. Molecular insights into the role of mitochondria in non-alcoholic fatty liver disease
    Jin Lee, Jeong-Su Park, Yoon Seok Roh · 2019 · Archives of Pharmacal Research
  68. Clinical trial: insulin‐sensitizing agents may reduce consequences of insulin resistance in individuals with non‐alcoholic steatohepatitis
    Ramazan Idılman, Dılşa Mızrak, D. CORAPCIOGLU, Mehmet Bektaş, Birsen Doğanay, Müyesser Saykı, Şahin Çoban, Esra Erden, İrfan Soykan, Rıfat Emral et al. · 2008 · Alimentary Pharmacology & Therapeutics
  69. Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice†
    Inmaculada García‐Ruíz, Cristina Rodríguez‐Juan, Teresa Díaz-Sanjuán, Miguel Ángel Martínez, Teresa Muñoz‐Yagüe, Jose Antonio Solis-Herruzo · 2007 · Hepatology
  70. Review article: diagnosis and treatment of non‐alcoholic fatty liver disease
    M. K. OH, Julie Winn, Fred F Poordad · 2008 · Alimentary Pharmacology & Therapeutics
  71. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease
    Ziya Omer, Şevki Çetinkalp, Murat Akyıldız, Funda Yılmaz, Yücel Batur, Candeğer Yılmaz, Ulus Salih Akarca · 2009 · European Journal of Gastroenterology & Hepatology
  72. The Clinicopathological Profile of Indian Patients with Nonalcoholic Fatty Liver Disease (NAFLD) is Different from That in the West
    Ajay Kumar. Duseja, Ashim Das, Reena Das, Radha Krishan Dhiman, Yogesh Kumar Chawla, Anil Kumar Bhansali, Naveen Kalra · 2007 · Digestive Diseases and Sciences
  73. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis
    Francesco Angelico, Marco Burattin, Cesare Alessandri, Maria Del Ben, Flavio Lirussi · 2007 · Cochrane Database of Systematic Reviews · Retracted
  74. Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: A systematic review
    Stergios A. Pοlyzos, Christos Socrates Mantzoros · 2016 · Metabolism
  75. Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future
    Melissa Davidson, Donald R. Mattison, Laurent Azoulay, Daniel R. Krewski · 2017 · Critical Reviews in Toxicology
  76. Mitochondrial involvement in non-alcoholic steatohepatitis
    Gaetano Serviddio, Juan Sastre, Francesco Bellanti, José Viña, Gianluigi Vendemiale, Emanuele Altomare · 2007 · Molecular Aspects of Medicine
  77. Meta-analysis of randomized controlled trials of pharmacologic agents in non-alcoholic steatohepatitis
    Said, Adnan, Akhter, Ahmed · 2017 · Annals of Hepatology
  78. Insulin resistance in development and progression of nonalcoholic fatty liver disease
    Shahinul Alam, Golam Mustafa, Mahabubul Alam, Nooruddin Ahmad · 2016 · World Journal of Gastrointestinal Pathophysiology
  79. An association between non‐alcoholic fatty liver disease and polycystic ovarian syndrome
    Malgorzata Monika Brzozowska, George Ostapowicz, Martin Weltman · 2009 · Journal of Gastroenterology and Hepatology
  80. Treatment of non-alcoholic fatty liver disease.
    2007 · PubMed Central
  81. Fatty liver is an independent risk factor for the development of Type 2 diabetes in Korean adults
    Chan‐Hee Kim, Jun-Young Park, K.-U. Lee, Ji Hoon Kim, H.‐K. Kim · 2008 · Diabetic Medicine
  82. New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD)
    Rafeeq Ali, Kenneth J. Cusi · 2009 · Annals of Medicine
  83. Nonalcoholic Fatty Liver Disease
    Krzysztof Lukasz Kopec, David L. Burns · 2011 · Nutrition in Clinical Practice
  84. Regulation of peroxisome proliferator-activated receptor-γ in liver fibrosis
    Liu Yang, Che–Chang Chan, Oh-Sang Kwon, Songling Liu, Jason McGhee, Stephen A. Stimpson, Lihong Z. Chen, W. Wallace Harrington, William T. Symonds, Don C. Rockey · 2006 · American Journal of Physiology-Gastrointestinal and Liver Physiology
  85. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats
    Yuka Hayashizaki, Eiji Kurosaki, Toshiyuki Takasu, Hikaru Mitori, Shunji Yamazaki, Kumi Koide, Shoji Takakura · 2015 · European Journal of Pharmacology
  86. Review: Treatment options for nonalcoholic fatty liver disease
    Brian P Lam, Zobair M. Younossi · 2010 · Therapeutic Advances in Gastroenterology
  87. Beneficial effects of probiotic combination with omega-3 fatty acids in NAFLD: a randomized clinical study
    Nazarii M. Kobyliak, Ludovico Abenavoli, Tetyana M. Falalyeyeva, Galyna Mykhalchyshyn, Luigi Boccuto, Liudmyla Kononenko, Dmytro Kyriienko, Iuliia Komisarenko, Oleh Dynnyk · 2018 · Minerva Medica
  88. Hepatitis C Virus Core Protein Modulates Fatty Acid Metabolism and Thereby Causes Lipid Accumulation in the Liver
    Atsushi Yamaguchi, Susumu Tazuma, Tomoji Nishioka · 2005 · Digestive Diseases and Sciences
  89. Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment
    Barbara Fruci, Stefania Giuliano, Angela Mazza, Roberta Malaguarnera, Antonino Belfiore · 2013 · International Journal of Molecular Sciences
  90. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
    Stephen A. Harrison, Brent A. Neuschwander‐Tetri · 2004 · Clinics in Liver Disease
  91. Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents
    Kristen J. Nadeau, Lindsay B. Ehlers, Philip Scott Zeitler, Kathy Love‐Osborne · 2008 · Pediatric Diabetes
  92. Effect of nutritional counselling on hepatic, muscle and adipose tissue fat content and distribution in non-alcoholic fatty liver disease
    Elizabeth Louise Thomas · 2006 · World Journal of Gastroenterology
  93. Alterations in the hypothalamic melanocortin pathway in amyotrophic lateral sclerosis
    Pauline Vercruysse, Jérôme Sinniger, Hajer El Oussini, Jelena Scekic‐Zahirovic, Stéphane Dieterle, Reinhard Dengler, Thomas Meyer, Stephan Zierz, Jan Kassubek, Wilhelm Fischer et al. · 2016 · Brain
  94. Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis
    Takeharu Asano, Kiyotaka Watanabe, Naoto Kubota, Toshiaki Gunji, Masao Omata, Takashi Kadowaki, Shin Ohnishi · 2009 · Journal of Gastroenterology and Hepatology
  95. Decreased Plasma Adiponectin Concentrations Are Closely Related to Steatosis in Hepatitis C Virus-Infected Patients
    Jean‐Michel Petit, Anne Minello, Valérie Jooste, Jean‐Baptiste Bour, Francoise Galland, Laurence Duvillard, Bruno L Vergès, Nils‐Olivier Olsson, Philippe Gambert, Patrick Hillon · 2005 · The Journal of Clinical Endocrinology & Metabolism
  96. Effects of interventions on intra- and interobserver agreement on interpretation of nonalcoholic fatty liver disease histology
    Samer Gawrieh, Darly M. Knoedler, Kia Saeian, James R. Wallace, RICHARD A. KOMOROWSKI · 2010 · Annals of Diagnostic Pathology
  97. Mechanisms of non-alcoholic steatohepatitis
    Craig James McClain, Sri Prakash Mokshagundam, Shirish S. Barve, Zhenyuan Song, Daniell B. Hill, Theresa Chen, Ion V. Deaciuc · 2004 · Alcohol
  98. Non-esterified fatty acid concentrations are independently associated with hepatic steatosis in obese subjects
    Helen Holt, Sarah H. Wild, P J Wood, Jia-Lu Zhang, Angela Darekar, Keith C Dewbury, Robin Poole, Richard I. G. Holt, David I. Phillips, Christopher D. Byrne · 2005 · Diabetologia
  99. Nonalcoholic steatohepatitis: pathologic features and differential diagnosis
    Elizabeth M. Brunt · 2005 · Seminars in Diagnostic Pathology
  100. Review article: the use of potentially hepatotoxic drugs in patients with liver disease
    N. K. GUPTA, James H. Lewis · 2008 · Alimentary Pharmacology & Therapeutics